White House Moves to Rewrite Federal Contracting Rules to Gain Lasting Control Over Research Funding

The Trump administration is pursuing changes to the Federal Acquisition Regulation, the foundational ruleset governing all federal contracts, that would give the executive branch broader authority to direct research priorities, terminate grants, and override external scientific review processes. The move follows earlier executive actions that faced legal challenges, and this regulatory pathway is designed to be more resistant to court intervention.

Why it matters

The Trump administration has shifted its strategy after early executive actions on research funding ran into legal resistance. Rather than relying on orders that courts can enjoin, the focus has moved to rewriting the Federal Acquisition Regulation itself. That regulation is the backbone of how the federal government enters into contracts and grants, and changes to it carry a different legal weight than a memo or an executive order.

For clinician-researchers and academic medical centers, the practical stakes are significant. Peer review as the primary mechanism for allocating federal research dollars has operated under an assumption of insulation from direct political override. If the regulatory foundation shifts, that assumption no longer holds. Institutions that have built research enterprise strategies around federal funding stability will need to think carefully about governance, diversification, and advocacy in ways that go beyond individual grant management.

What to watch

Whether professional societies and research universities mount a coordinated regulatory comment response before any proposed rule is finalized, and whether Congress signals any appetite to codify peer review independence into statute.